A method for treating pain, inflammation, fever and respiratory complaints in mammals comprising administering by needleless injection to a mammal in need of such treatment an aqueous cyclodextrin-free solution of meloxicam containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base.

A method for treating pain inflammation fever and respiratory complaints in mammals comprising administering by needleless injection to a mammal in need of such treatment an aqueous cyclodextrin-free solution of meloxicam containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base.

Disclosed herein are materials and methods for treating patients that have been exposed to pathological levels on ionizing radiation. These materials and methods include administering to a patient in thereof at least one dose of a compound such as prostaglandin (PGE2) as soon as possible after the patient has been exposed to the radiation. Additional embodiments include treating a patient exposed to radiation with at least one dose of a compound that modulates PGE2 activity such as non-steroidal...

Water soluble meloxicam granules comprising: (a) meloxicam; (b) a salt forming agent which forms the meglumine sodium potassium or ammonium salt of meloxicam; (c) a binder; (d) a sugar or sweetener; and (e) a carrier and optionally a flavoring agent and optionally other excipients processes for preparing them and their use for treating respiratory or inflammatory complaints in mammals.

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereo...

The present invention comprises both meloxicam and xylazine containing compositions and methods of their administration in the field of veterinary pharmaceuticals. A meloxicam and xylazine formulation is provided which is adapted for oral administration. A method is also provided to form a combination meloxicam and xylazine formulation from meloxicam and xyalzine formulations including directions as to concentrations and dosages for sheep and cattle, the target species for the formulations.

The invention provides pharmaceutical compositions comprising a therapeutically effective amount of meloxicam or a pharmaceutically acceptable salt thereof wherein the pharmaceutical compositions are in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity. Also provided are processes for preparing a pharmaceutical composition of the invention. Further provided are methods of treating arthritis or pain in a subject in need thereof the method co...

Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients the content of dissolved meloxicam salt being more than 10 mg/ml. The formulation according to the invention has a shelf-life of up to 24 months or more.

Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions as well as a method to treat pet animals particularly dogs and cats. Compositions of the present invention are particularly useful for administration to provide animals with dosages of about 1.0 to 50 mg of compound A/kg of body weight of...